

Resource Summary Report

Generated by [NIF](#) on Sep 17, 2026

HCC95

RRID:CVCL_5137

Type: Cell Line

Proper Citation

RRID:CVCL_5137

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_5137

Proper Citation: RRID:CVCL_5137

Description: Cell line HCC95 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung squamous cell carcinoma

Defining Citation: [PMID:9559342](#), [PMID:10353731](#), [PMID:10987304](#), [PMID:16187286](#), [PMID:19472407](#), [PMID:20557307](#), [PMID:20679594](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:24002593](#), [PMID:25877200](#), [PMID:26361996](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:29610121](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31803961](#), [PMID:31978347](#)

Comments: Caution: Indicated as originating from a 65 year old male patient in PubMed=10353731 and from a 70 year old in PubMed=9559342., Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC95

Synonyms: HCC-95, HCC0095, Hamon Cancer Center 95

Cross References: BTO:BTO_0006027, EFO:EFO_0003138, ArrayExpress:E-MTAB-2770, BioGRID_ORCS_Cell_line:423, BioSample:SAMN03470831,

BioSample:SAMN10987960, cancercellines:CVCL_5137, Cell_Model_Passport:SIDM01593, ChEMBL-Cells:ChEMBL4295471, ChEMBL-Targets:ChEMBL4296387, Cosmic:877260, Cosmic:903628, Cosmic:1146942, Cosmic:1219070, Cosmic:1239909, Cosmic:1608838, Cosmic:2060521, Cosmic:2125264, Cosmic:2696403, DepMap:ACH-000454, GEO:GSM62969, GEO:GSM108885, GEO:GSM108886, GEO:GSM253404, GEO:GSM434322, GEO:GSM794376, GEO:GSM817112, GEO:GSM887061, GEO:GSM888131, GEO:GSM1374513, IARC_TP53:28445, IGRhCellID:HCC95_GEO, KCLB:70095, LiGeA:CCLE_512, Millipore:SCC483, Pharmacodb:HCC95_463_2019, PRIDE:PXD002556, Progenetix:CVCL_5137, PubChem_Cell_line:CVCL_5137, Wikidata:Q54881826

ID: CVCL_5137

Record Creation Time: 20220427T220320+0000

Record Last Update: 20260913T003954+0000

Ratings and Alerts

No rating or validation information has been found for HCC95.

No alerts have been found for HCC95.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Zeng J, et al. (2026) KLF5 Activation Promotes Malignant Transformation to Drive Development of Lung Squamous Cell Carcinoma. Cancer research, 86(7), 1622.

Hofman DA, et al. (2024) Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. Molecular cell, 84(2), 261.

DuCote TJ, et al. (2024) EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas. Cancer research communications, 4(2), 388.

Pan Y, et al. (2023) KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition. Cancer cell, 41(1), 88.

Hofman DA, et al. (2023) Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. bioRxiv : the preprint server for biology.

Schram AM, et al. (2022) Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. *Cancer discovery*, 12(5), 1233.

Liang Y, et al. (2022) Self-restricted circular RNA circSOX2 suppressed the malignant progression in SOX2-amplified LUSC. *Cell death & disease*, 13(10), 873.

Gozgit JM, et al. (2021) PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. *Cancer cell*, 39(9), 1214.

Torres-Ayuso P, et al. (2021) TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through Merlin. *Cancer discovery*, 11(6), 1411.

Odintsov I, et al. (2021) The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 27(11), 3154.

Yenerall P, et al. (2020) RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. *Cell chemical biology*, 27(1), 105.

Updegraff BL, et al. (2018) Transmembrane Protease TMPRSS11B Promotes Lung Cancer Growth by Enhancing Lactate Export and Glycolytic Metabolism. *Cell reports*, 25(8), 2223.

Unni AM, et al. (2018) Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells. *eLife*, 7.